Qilu Pharmaceutical Co., Ltd was Arbutus Biopharma’s largest revenue line in fiscal 2025, bringing in $10.43M of $14.08M (74%).
| Counterparty Name | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Monsanto | — | — | — | — | ||||||
| Qilu Pharmaceutical Co., Ltd | — | $10.70M | $1.40M | $10.43M | ||||||
| Qilu Pharmaceutical Co, Ltd | $26.02M | — | — | — | ||||||
| Alexion | — | — | — | — | ||||||
| Dod | — | — | — | — | ||||||
| Onpattro Non Cash Royalty | — | $3.87M | $2.25M | $1.48M | ||||||
| Onpattro - Non-Cash Royalty | $7.65M | — | — | — | ||||||
| Onpattro Cash Royalty | — | $3.61M | $2.56M | $1.67M | ||||||
| Onpattro - Cash Royalty | $5.32M | — | — | — | ||||||
| Acuitas Therapeutics, Inc | — | — | — | — | ||||||
| Alnylam Pharmaceuticals, Inc | — | — | — | — | ||||||
| Gritstone Oncology, Inc | — | — | — | — | ||||||
| Gritstone | — | — | — | — | ||||||
| Dicerna | — | — | — | — | ||||||
| Acrotech Biopharma, Llc | — | — | — | — | ||||||
| Other Milestone & Royalty Payments | — | — | — | $500.00K | ||||||
| Other Milestones & Royalty Payments | $35.00K | — | — | — | ||||||
| Other | — | — | — | — | ||||||
| Total | $39.02M | $18.18M | $6.21M | $14.08M |
Arbutus Biopharma brought in $14.08M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Arbutus Biopharma regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $6.21M. Qilu Pharmaceutical Co., Ltd was the largest at $10.43M (74.1%), ahead of Onpattro Cash Royalty at $1.67M (11.8%) and Onpattro Non Cash Royalty at $1.48M (10.5%). The remaining revenue line, Other Milestone & Royalty Payments, brought in $500.00K.
Compared with fiscal 2024, Qilu Pharmaceutical Co., Ltd grew fastest, up 645.3% to $10.43M, while Onpattro Cash Royalty fell the most, down 34.9% to $1.67M.
Arbutus Biopharma began breaking out Qilu Pharmaceutical Co., Ltd in fiscal 2023, Onpattro Non Cash Royalty in fiscal 2023 and Onpattro Cash Royalty in fiscal 2023. Arbutus Biopharma stopped reporting Qilu Pharmaceutical Co, Ltd ($26.02M in fiscal 2022), Onpattro - Non-Cash Royalty ($7.65M in fiscal 2022), Onpattro - Cash Royalty ($5.32M in fiscal 2022) and one other as separate revenue lines.
Collaborations & Licenses was Arbutus Biopharma’s largest product and service line in fiscal 2025, bringing in $12.60M of $14.08M (89%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Collaborations & Licenses | $31.37M | $14.27M | $3.92M | $12.60M | ||||
| Collaboration & Contracts | — | — | — | — | ||||
| Non-Cash Royalty Revenue | $7.65M | $3.87M | $2.25M | $1.48M | ||||
| Total | $39.02M | $18.14M | $6.17M | $14.08M |
Arbutus Biopharma brought in $14.08M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 128.2% from $6.17M in fiscal 2024. Collaborations & Licenses was the largest at $12.60M (89.5%), ahead of Non-Cash Royalty Revenue at $1.48M (10.5%).
Compared with fiscal 2024, Collaborations & Licenses grew 221.5% to $12.60M, while Non-Cash Royalty Revenue fell 34.2% to $1.48M. From fiscal 2022 to 2025, combined revenue from these lines fell from $39.02M to $14.08M, a compound annual decline of 28.8%. Collaborations & Licenses' share of the total rose from 80.4% to 89.5%.
Quarter Four was Arbutus Biopharma’s largest revenue line in fiscal 2013, bringing in $7.53M of $15.46M (49%).
| Quarterly Reporting | FY 2012 | FY 2013 |
|---|---|---|
| Quarter Four | $3.81M | $7.53M |
| Quarter Two | $3.64M | $2.84M |
| Quarter Three | $3.07M | $2.96M |
| Quarter One | $3.59M | $2.13M |
| Total | $14.11M | $15.46M |
Arbutus Biopharma brought in $15.46M from its four revenue lines in fiscal 2013, the year ended December 31, 2013. That was up 9.6% from $14.11M in fiscal 2012. Quarter Four was the largest at $7.53M (48.7%), ahead of Quarter Three at $2.96M (19.2%) and Quarter Two at $2.84M (18.4%). The remaining revenue line, Quarter One, brought in $2.13M.
Compared with fiscal 2012, Quarter Four grew fastest, up 97.7% to $7.53M, while Quarter One fell the most, down 40.6% to $2.13M.
Arbutus Biopharma (ABUS) reports its revenue by counterparty name, by product and service and by quarterly reporting. In fiscal 2025, Qilu Pharmaceutical Co., Ltd was its largest revenue line, bringing in $10.43M (74.1% of the total), followed by Onpattro Cash Royalty at $1.67M (11.8%).
Qilu Pharmaceutical Co., Ltd was Arbutus Biopharma's largest revenue line in fiscal 2025, bringing in $10.43M, or 74.1% of the $14.08M total across its four revenue lines.
Collaborations & Licenses was Arbutus Biopharma's largest product and service line in fiscal 2025, bringing in $12.60M, or 89.5% of the $14.08M total across its two product and service lines.
Collaborations & Licenses grew faster than Non-Cash Royalty Revenue in fiscal 2025, up 221.5% from $3.92M to $12.60M. Non-Cash Royalty Revenue fell 34.2% to $1.48M.
Every figure comes from Arbutus Biopharma's annual financial filings, as reported. Each line keeps the name Arbutus Biopharma gives it, and years follow its fiscal calendar.
Arbutus Biopharma's revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.